TherapeuticsMD Announces Fourth Quarter and Full-Year 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks gain, oil prices slide
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
TherapeuticsMD (TXMD) Reports In-Line Q4 EPS
February 23, 2017 6:46 AM ESTTherapeuticsMD (NYSE: TXMD) reported Q4 EPS of ($0.12), in-line with the analyst estimate of ($0.12). Revenue for the quarter came in at $4.49 million versus the consensus estimate of $5.91 million.
For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.
... More